EU pressure to restrict trade with Israeli settlements is moving from headline risk to a real policy question, and that matters for your portfolio. Companies tied to EU Israel cross border supply chains face potential import bans, tariffs, or new licensing hurdles, all of which can hit costs, volumes, or pricing power. This article looks at 3 stocks exposed to these trade policy risks, explaining where regulatory decisions could threaten revenue streams, disrupt sourcing, or reshape market access, so you can judge whether the current uncertainty makes them candidates to avoid, reassess, or monitor more closely.
Overview: Shufersal is Israel's largest supermarket operator, running a nationwide chain of Shufersal branded stores and an online platform that sell food, household goods, personal care items, electronics, and other non food products, alongside a credit card and customer club business.
Operations: Shufersal generates the bulk of its ₪14.5b revenue from retail chains in Israel, with a smaller ₪280m contribution from real estate activities.
Market Cap: ₪11.6b
Shufersal looks interesting on price, with shares trading well below one DCF based fair value estimate and supported by high quality earnings and an 18.8% ROE. However, the risks are hard to ignore. The company is tightly linked to Israeli supply chains that may be affected by any EU move to restrict trade with settlements, which could influence sourcing, margins, and brand perception in export channels. Recent quarterly numbers show revenue of ₪3,688m and modestly higher net margins. Yet the stock has lagged both the wider Israeli market and local consumer retailers, and carries a capital structure fully reliant on external borrowing at a time when regulatory and funding shocks are front of mind for many investors.
Shufersal’s high ROE and seemingly cheap shares may be masking deeper exposure to EU settlement trade risks and funding pressures. Before assuming the stock is mispriced, review the 2 key rewards and 1 important warning sign
Overview: ICL Group is a global fertilizer and specialty minerals company that turns potash, phosphate, bromine and related chemicals into products used across agriculture, food, industrial and consumer markets. It supplies everything from crop nutrients and soil conditioners to flame retardants and water treatment chemicals, serving customers in many industries worldwide.
Operations: ICL Group generates most of its revenue from Phosphate Solutions at US$2.4b and Growing Solutions at US$2.1b, with additional contributions from Potash at US$1.8b and Industrial Products at US$1.3b, partly offset by a US$408m reconciliation adjustment.
Market Cap: ₪18.8b
ICL Group might catch your eye because it screens as cheap relative to some peers and has secured long term supply deals, such as its recent agreement to ship hundreds of thousands of tons of potash to India. However, the story behind that value signal is uncomfortable. Profit margins are thin at 3.5%, earnings have fallen sharply over several years, and the company carries meaningful debt, recently adding US$800m of 6.036% senior notes that keep it tied to external funding markets. At the same time, any EU move against goods linked to Israeli settlements could affect exports and logistics for a business already juggling Red Sea shipping risks. This leaves investors to consider whether the low P/E reflects compensation for these pressures or a warning sign that more trouble is being priced in.
ICL Group’s thin margins and fresh US$800m bond issue suggest the low P/E might not be a bargain; it might be a warning. Get the fuller picture with the 2 key rewards and 5 important warning signs (1 is major!)
Overview: Rami Levi Chain Stores Hashikma Marketing 2006 operates a nationwide chain of discount supermarkets in Israel, selling food, fresh produce, household and cleaning products, toiletries, clothing, housewares and other everyday goods. The company also provides franchise services under its brand.
Operations: Rami Levi Chain Stores Hashikma Marketing 2006 generates most of its ₪8.1b revenue from its retail chains segment at approximately ₪7.2b, with additional contributions from Good Pharm at ₪540.5m and other activities at ₪416.0m, partly offset by consolidation adjustments.
Market Cap: ₪5.0b
Rami Levi Chain Stores Hashikma Marketing 2006 might attract attention with a high 39% ROE, solid Q1 2026 results and a share price that screens below one fair value estimate. However, the picture is more complicated. Profit margins are slim at 2.8% and have narrowed, the dividend track record is unstable and funding relies entirely on higher risk external borrowing. This can be uncomfortable when regulatory shocks are on the table. Heavy operational exposure to Israeli settlements means any EU trade restrictions could affect specific product lines or logistics just as investors are trying to make sense of an above average P/E and governance concerns from a long tenured, less independent board.
Rami Levi’s high 39% ROE and thin 2.8% margins could be masking how exposed the business is to EU settlement trade risk and funding stress, so read the 1 key reward and 1 important warning sign for the potential twist investors may be missing
If Shufersal or any of these companies are making you feel more cautious, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Fresh stock ideas can move from quiet to crowded fast, as momentum builds and under the radar stories get caught by the crowd. Scan these curated lists and get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com